• Something wrong with this record ?

Heart valve tissue engineering: how far is the bedside from the bench

A. Sanz-Garcia, J. Oliver-de-la-Cruz, V. Mirabet, C. Gandía, A. Villagrasa, E. Sodupe, C. Escobedo-Lucea,

. 2015 ; 17 (-) : e16. [pub] 20150924

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc16009955
E-resources Online Full text

NLK ProQuest Central from 2001-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2001-01-01 to 1 year ago

Links

PubMed 26399177
DOI 10.1017/erm.2015.15
Knihovny.cz E-resources

Heart disease, including valve pathologies, is the leading cause of death worldwide. Despite the progress made thanks to improving transplantation techniques, a perfect valve substitute has not yet been developed: once a diseased valve is replaced with current technologies, the newly implanted valve still needs to be changed some time in the future. This situation is particularly dramatic in the case of children and young adults, because of the necessity of valve growth during the patient's life. Our review focuses on the current status of heart valve (HV) therapy and the challenges that must be solved in the development of new approaches based on tissue engineering. Scientists and physicians have proposed tissue-engineered heart valves (TEHVs) as the most promising solution for HV replacement, especially given that they can help to avoid thrombosis, structural deterioration and xenoinfections. Lastly, TEHVs might also serve as a model for studying human valve development and pathologies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16009955
003      
CZ-PrNML
005      
20160413113640.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1017/erm.2015.15 $2 doi
024    7_
$a 10.1017/erm.2015.15 $2 doi
035    __
$a (PubMed)26399177
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sanz-Garcia, Andres $u Division of Pharmaceutical Biosciences,Faculty of Pharmacy,University of Helsinki,Viikinkaari 5 E,P.O. Box 56,00014 Helsinki,Finland.
245    10
$a Heart valve tissue engineering: how far is the bedside from the bench / $c A. Sanz-Garcia, J. Oliver-de-la-Cruz, V. Mirabet, C. Gandía, A. Villagrasa, E. Sodupe, C. Escobedo-Lucea,
520    9_
$a Heart disease, including valve pathologies, is the leading cause of death worldwide. Despite the progress made thanks to improving transplantation techniques, a perfect valve substitute has not yet been developed: once a diseased valve is replaced with current technologies, the newly implanted valve still needs to be changed some time in the future. This situation is particularly dramatic in the case of children and young adults, because of the necessity of valve growth during the patient's life. Our review focuses on the current status of heart valve (HV) therapy and the challenges that must be solved in the development of new approaches based on tissue engineering. Scientists and physicians have proposed tissue-engineered heart valves (TEHVs) as the most promising solution for HV replacement, especially given that they can help to avoid thrombosis, structural deterioration and xenoinfections. Lastly, TEHVs might also serve as a model for studying human valve development and pathologies.
650    _2
$a zvířata $7 D000818
650    12
$a bioprotézy $7 D001705
650    _2
$a dítě $7 D002648
650    _2
$a kolagen $x chemie $7 D003094
650    _2
$a endoteliální buňky $x cytologie $x fyziologie $7 D042783
650    _2
$a fetální krev $x cytologie $x fyziologie $7 D005312
650    _2
$a fibrin $x chemie $7 D005337
650    12
$a srdeční chlopně umělé $7 D006350
650    _2
$a srdeční chlopně $x patologie $x chirurgie $7 D006351
650    _2
$a lidé $7 D006801
650    _2
$a kyselina hyaluronová $x chemie $7 D006820
650    _2
$a indukované pluripotentní kmenové buňky $x cytologie $x fyziologie $7 D057026
650    _2
$a ovce $7 D012756
650    _2
$a prasata $7 D013552
650    _2
$a tkáňové inženýrství $x metody $7 D023822
650    12
$a tkáňové podpůrné struktury $7 D054457
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Oliver-de-la-Cruz, Jorge $u International Clinical Research Center,Integrated Center of Cellular Therapy and Regenerative Medicine,St. Anne's University Hospital,Brno,Czech Republic.
700    1_
$a Mirabet, Vicente $u Cell and Tissue Bank,Regional Transfusion Center,Valencia,Spain.
700    1_
$a Gandía, Carolina $u Division of Pharmaceutical Biosciences,Faculty of Pharmacy,University of Helsinki,Viikinkaari 5 E,P.O. Box 56,00014 Helsinki,Finland.
700    1_
$a Villagrasa, Alejandro $u Hospital Fundación Jimenez Diaz,IIS-FJD,28040 Madrid,Spain.
700    1_
$a Sodupe, Enrique $u EDMANS Group,University of La Rioja,C/Luis de Ulloa 20,26004 Logrono,Spain.
700    1_
$a Escobedo-Lucea, Carmen $u Division of Pharmaceutical Biosciences,Faculty of Pharmacy,University of Helsinki,Viikinkaari 5 E,P.O. Box 56,00014 Helsinki,Finland.
773    0_
$w MED00174439 $t Expert reviews in molecular medicine $x 1462-3994 $g Roč. 17, č. - (2015), s. e16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26399177 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160413113724 $b ABA008
999    __
$a ok $b bmc $g 1113384 $s 934323
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 17 $c - $d e16 $e 20150924 $i 1462-3994 $m Expert reviews in molecular medicine $n Expert Rev Mol Med $x MED00174439
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options